147 related articles for article (PubMed ID: 30364868)
1. The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease.
Jørgensen J; Servos S; Kefalas P
J Mark Access Health Policy; 2018; 6(1):1500419. PubMed ID: 30364868
[No Abstract] [Full Text] [Related]
2. Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2017; 5(1):1355203. PubMed ID: 28839525
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England.
Cherla A; Renwick M; Jha A; Mossialos E
EClinicalMedicine; 2020 Dec; 29-30():100625. PubMed ID: 33437948
[TBL] [Abstract][Full Text] [Related]
4. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
5. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
Ha SY; Kang DW; Jung HI; Lee EK; Park MH
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
8. How reliable are ICER's results published in current pharmacoeconomic literature? The controversial issue of price confidentiality.
Russo P
Glob Reg Health Technol Assess; 2022; 9():31-35. PubMed ID: 36628320
[TBL] [Abstract][Full Text] [Related]
9. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
10. Value-based differential pricing: efficient prices for drugs in a global context.
Danzon P; Towse A; Mestre-Ferrandiz J
Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
[TBL] [Abstract][Full Text] [Related]
11. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
12. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
Danzon PM
Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Noyes K; Dick AW; Holloway RG;
Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
[TBL] [Abstract][Full Text] [Related]
14. Approaches to manage 'affordability' of high budget impact medicines in key EU countries.
Flume M; Bardou M; Capri S; Sola-Morales O; Cunningham D; Levin LA; Postma MJ; Touchot N
J Mark Access Health Policy; 2018; 6(1):1478539. PubMed ID: 29915664
[No Abstract] [Full Text] [Related]
15. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
16. Drug Policy in the Czech Republic.
Skoupá J
Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
[TBL] [Abstract][Full Text] [Related]
17. Aligning opportunity cost and net benefit criteria: the health shadow price.
Eckermann S
Front Public Health; 2024; 12():1212439. PubMed ID: 38510345
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]